United Therapeutics and MannKind Announce Closing of License and Collaboration Agreement

Pharmaceutical Investing

United Therapeutics (Nasdaq: UTHR) and MannKind (Nasdaq: MNKD) announced the closing of their pending worldwide exclusive license and collaboration agreement for the development and commercialization of Treprostinil Technosphere, a dry powder formulation of treprostinil being developed for the treatment of pulmonary arterial hypertension. As quoted in the press release: As previously announced, the effectiveness of …

United Therapeutics (Nasdaq: UTHR) and MannKind (Nasdaq: MNKD) announced the closing of their pending worldwide exclusive license and collaboration agreement for the development and commercialization of Treprostinil Technosphere, a dry powder formulation of treprostinil being developed for the treatment of pulmonary arterial hypertension.

As quoted in the press release:

As previously announced, the effectiveness of the agreement was conditioned upon expiration or termination of the required waiting period under the Hart-Scott-Rodino Antitrust Improvements Act. The requisite waiting period expired on October 15, 2018, and the agreement became effective the same day.

Click here to read the full press release.

The Conversation (0)
Ă—